Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies
| dc.rights.license | open | en_US |
| dc.contributor.author | LAMBERT-NICLOT, S. | |
| dc.contributor.author | GRUDE, M. | |
| dc.contributor.author | MEYNARD, J. L. | |
| dc.contributor.author | MARCELIN, A. G. | |
| dc.contributor.author | VALANTIN, M. A. | |
| dc.contributor.author | FLANDRE, P. | |
| dc.contributor.author | IZOPET, J. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MOINOT, Laetitia | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BOUTELOUP, Vincent | |
| dc.contributor.author | CALVEZ, V. | |
| dc.contributor.author | KATLAMA, C. | |
| dc.contributor.author | GIRARD, P. M. | |
| dc.contributor.author | MORAND-JOUBERT, L. | |
| dc.date.accessioned | 2020-11-23T15:14:59Z | |
| dc.date.available | 2020-11-23T15:14:59Z | |
| dc.date.issued | 2018-11-28 | |
| dc.identifier.issn | 1537-6591 (Electronic) 1058-4838 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/15584 | |
| dc.description.abstractEn | Background: We pooled the results of three randomized trials that compared the efficacy of PI/r monotherapy and standard triple therapy as maintenance therapy and evaluated: 1) the distribution of ultrasensitive viral load (USVL) at week 96 (W96), 2) factors associated with virological success (VL<50 copy/mL) at W96, and 3) factors associated with USVL<1 copy/ml (c/ml) at W96. Methods: Virological failure was defined as two consecutive measurements of HIV-1 RNA viral load >50 copies/mL and was analyzed in intention-to-treat. USVL was measured with commercial standard Roche assay. A logistic model was used to investigate which variables were predictive of VF. The Fisher exact test was used to investigate differences in USVL at W96. Results: Among 609 patients, 73% were male with a median age of 44.4 years (IQR 39.8-52.1), the treatment duration was four years, (2.4-7.6), baseline CD4/CD8 ratio 0.8 (0.6-1.10), baseline CD4 cell count 564/mm3 (422-707), and 59% presented a baseline USVL<1 copy/mL. At W96, the proportion of USVL<1 copy/mL was significantly lower for PI/r monotherapy than triple therapy (65% versus 74%; p=0.04). Overall, baseline USVL<1 copy/mL, triple therapy, and being female were associated with an USVL<1 copy/mL at W96 (p<0.0001, p=0.049 and p=0.006). For PI/r monotherapy, receiving DRV/r rather than LPV/r was associated with an USVL<1 copy/mL at W96 (p=0.03). Factors associated with virological success at W96 were higher baseline CD4 cell count (p=0.034) and baseline USVL<1 copy/mL (p=0.0005). Conclusion: Although PI/r monotherapy is not widely recommended, this strategy is still sometimes used and USVL determination for virologically-controlled patients may help to select the best candidates for PI/r monotherapy. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | USMR | |
| dc.title.en | Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies | |
| dc.title.alternative | Clin Infect Dis | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1093/cid/ciy382 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 29767684 | en_US |
| bordeaux.journal | Clinical infectious diseases | en_US |
| bordeaux.page | 1883-1889 | en_US |
| bordeaux.volume | 67 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 12 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | USMR | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20infectious%20diseases&rft.date=2018-11-28&rft.volume=67&rft.issue=12&rft.spage=1883-1889&rft.epage=1883-1889&rft.eissn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.issn=1537-6591%20(Electronic)%201058-4838%20(Linking)&rft.au=LAMBERT-NICLOT,%20S.&GRUDE,%20M.&MEYNARD,%20J.%20L.&MARCELIN,%20A.%20G.&VALANTIN,%20M.%20A.&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||